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Toward supramolecular nanozymes for the
photocatalytic activation of Pt(IV) anticancer
prodrugs†
Laura F. Mazzei,abc Álvaro Martı́nez,*a Lucia Trevisan, c Daniele Rosa-Gastaldo, c
Aitziber L. Cortajarena, bd Fabrizio Mancin *c and Luca Salassa *ade
A supramolecular nanozyme for the photocatalytic conversion of
a Pt(IV) anticancer complex to cisplatin is described herein. We
employed 1.9 nm Au nanoparticles decorated with thiol ligands
bearing a TACN (1,4,7-triazacyclononane) headgroup to encapsulate
FMN (riboflavin-50-phosphate). In the presence of an electron donor,
flavin-loaded nanoparticles photocatalyzed the reductive activation of
the prodrug cis,cis,trans-[Pt(NH3)2(Cl2)(O2CCH2CH2COOH)2] to cispla-
tin, achieving turnover frequency values of 7.4 min1.
Bioorthogonal nanozymes are nm-sized catalysts capable of
performing artificial reactions in biological media.1 To date,
nanozymes have been fabricated by entrapping metallic nano-
particles (e.g. Pd, Au, Cu) into polymer matrixes,2–4 by decorat-
ing nanometric Au scaffolds with catalytic units5 or by
encapsulating organometallic catalysts (e.g. Ru, Pd complexes)
in the coating ligand shell.6 Especially in the latter case, the
nanostructure is fundamental to improve the solubility of the
embedded catalyst and to protect it from poisoning reactions
that easily occur in biological environments.7 Besides, proper
design of the nanozyme enables controlling the localization of
the molecular catalyst in specific cellular compartments3,8 or
tissues9 and triggering their catalytic activity upon external
stimuli.6 To the best of our knowledge, bioorthogonal nano-
zymes developed so far catalyze the deprotection of caged
organic imaging and therapeutic agents or promote the in situ
synthesis of drug derivatives.1,4,10
We recently reported a novel type of bioorthogonal photo-
catalytic reactions in which flavins (e.g. riboflavin, FMN and
FAD) and certain flavoproteins transform Pt(IV) precursors into
the clinically approved anticancer drugs cisplatin and carbo-
platin in biological media (Fig. 1A).11–13 As rarely observed in
catalysis,14,15 metal complexes act as substrates rather than
catalysts in these unconventional processes. Mechanistic stu-
dies highlighted that light excitation of flavins in the presence
Fig. 1 (A) Photocatalytic activation scheme of the cisplatin prodrug cis,cis,-
trans-[Pt(NH3)2(Cl2)(O2CCH2CH2COOH)2] (1); (B) photocatalyst (FMN) and Au
nanoparticles decorated with a C11-thiol bearing a 1,4,7-triazacyclononane
headgroup (TACN AuNPs); (C) schematic representation of the nanozyme
developed in this work.
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of an electron donor (e.g. zwitterionic buffers or NADH) affords
the doubly-reduced flavin form (Fig. 1A) which is the active
catalyst prompting the bioorthogonal substrate conversion.11,13
In vitro experiments also demonstrated that this activation
strategy hold promise for its capacity to deliver lethal concen-
trations of Pt drugs with minimal light doses.11,16
The relevance of Pt(IV) complexes in photochemotherapy
research is proved by the numerous photoactivatable prodrugs
and activation approaches developed in recent years.17–20
Motivated by these results and the progress in the design of
nanomaterials with enzyme-like features, we report herein our
first steps in the implementation of photocatalysis towards
Pt substrates by nanozymes. To such aim, we selected FMN,
1.9 nm Au nanoparticles decorated with a C11-thiol bearing a
1,4,7-triazacyclononane headgroup (TACN AuNPs), and the
complex cis,cis,trans-[Pt(NH3)2(Cl2)(O2CCH2CH2COOH)2] (1) as
photocatalyst, nanozyme scaffold, and substrate, respectively
(Fig. 1A and B; Fig. S1 and S2, ESI†).
We opted for spherical nanoparticles with a Au core smaller
than 2 nm to have a nanoplatform size in the biomolecular
scale and to minimize light absorption and scattering by the
nanoparticles due to the surface plasmon band, whose inten-
sity depends on the nanoparticle size.21 Previously, Rotello and
co-workers used similar AuNPs for the controlled photodelivery
of anticancer drugs using UV-A light.22 NMR sensing studies on
TACN AuNPs closely related to the ones used in this work
showed that FMN strongly binds to the thiol monolayer via
electrostatic and hydrophobic interactions.23 When in the
protonated form (TACNNH pKa 10.4, 6.8, 2.4)
24 or bound to
Zn2+, the positively charged TACN group can interact with the
negatively charged phosphate of the FMN ribityl sidechain,
while the hydrophobic environment provided by the C11 alkyl
spacer of the ligand can accommodate the aromatic isoallox-
azine ring system of FMN. Likewise, 1 is also capable of
electrostatically binding the TACN headgroups, since the suc-
cinato ligands of the complex are deprotonated at pH above 6.25
Therefore, TACN AuNPs are valuable candidates to operate as
supramolecular nanoscaffolds that favor co-localization of FMN
and 1, ultimately affording a nanozyme for the photocatalytic
conversion of a Pt(IV) prodrug into cisplatin (Fig. 1C).
To test this hypothesis and assemble the nanozyme, we
firstly investigated the loading of FMN onto TACN AuNPs
(100 mM of TACN ligand) in MES buffer (5 mM, pH 6) by
fluorescence quenching measurements. These experiments
were performed in the absence and presence of 1 equivalent
of Zn(NO3)2 (100 mM), that is with the amino groups of TACN
positively charged due to protonation (FMN@TACN AuNPs) or
coordination of Zn2+ (FMN@Zn-TACN AuNPs) respectively.
MES was selected since it acts as electron donor in the
Pt(IV) - Pt(II) catalytic conversion and protects flavins from
photodecomposition.11,26 Upon interaction with TACN AuNPs,
FMN fluorescence emission (lem = 527 nm) was quenched by
the Au core of the nanoparticles, enabling determination of the
FMN concentration at which the nanoscaffold binding sites are
saturated. After correcting FMN emission intensity for inner
filter effect27 (Fig. S3, ESI†), we found saturation concentrations
to be in the 50–60 mM range for both types of TACN AuNPs.
Furthermore, DOSY and NOE-pumping NMR experiments con-
firmed the anticipated interaction between TACN AuNPs and 1
(Fig. 2 and Fig. S4, ESI†), including under the condition
employed in catalysis tests (vide infra). As expected for such a
scenario, signals of 1 undergo a relevant broadening in the
presence of TACN AuNPs (Fig. S4, ESI†) and the diffusion rate
of 1 determined by DOSY decreased up to ca. 4 times in the
presence of the nanoparticles with respect to the free complex
(1.26  1010 vs. 4.15  1010 m2 s1). NOE pumping unequi-
vocally demonstrated the fast exchange of nanoparticle-bound
1 in the NMR time scale. In fact, magnetization transfer from
the AuNPs to the metal complex can only be observed in the
case of close (o4 Å) and sufficiently prolonged contacts.
For testing the catalytic performance of the nanozyme, we
hence loaded the nanoparticles with 25 mM FMN, a concen-
tration considerably below the saturation limit to avoid the
presence of free catalyst in solution during the reaction. The
concentration of substrate 1 was fixed at 500 mM to allow
monitoring the photocatalysis progression by 1H-NMR. Impor-
tantly, fluorescence control experiments showed that FMN is
not significantly displaced by 1 at such concentrations (Fig. S5,
ESI†), confirming the higher affinity of the TACN AuNPs for
amphiphilic guests as FMN than for hydrophilic guests as 1.28,29
Under these conditions, we evaluated the capacity of the
flavonanozymes to photocatalytically activate 1 upon irradiation
with blue light (460 nm, 5.30 mW cm2) and compared their
efficiency with 25 mM of free FMN (Fig. 3 and Fig. S6, ESI†).
Substrate conversion was monitored by quantifying the
release of succinato ligands by 1H-NMR as a function of the
irradiation time. Previous work demonstrated that this process
corresponded to the generation of cisplatin.16
FMN@TACN and FMN@Zn-TACN AuNPs displayed an
almost identical behavior in terms of catalytic activity, reaching
80% conversion already within 7 min and a plateau at 90%
conversion after 30 min of light irradiation. These data corre-
sponded to a turnover number (TON) of 18 and turnover
frequency (TOF) of 7.4 min1 (calculated in the range 15–45%
Fig. 2 DOSY spectra of 1 in the absence (A) or presence (B) of TACN
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conversion). Similar TON and TOF values were obtained for free
FMN under the same conditions. Furthermore, we investigated
the stability of the nanozymes under light irradiation to discard
leaking of FMN from the AuNPs during catalysis (Fig. 4). In the
presence of TACN AuNPs, the fluorescence emission of FMN
remained quenched throughout the whole light-irradiation
time window, thus demonstrating that the catalyst was associated
to the nanozyme scaffold during such period. In addition, the
emission intensity of FMN@TACN AuNPs underwent a further
slight decrease over time due to FMN photodegradation,11 with
almost complete depletion after 10 min. However, the process
occurred at a lower rate than for free FMN (Fig. 4, inset plot),
suggesting a moderate protecting effect of the AuNPs towards
FMN photobleaching. We speculate that such increase in stability
positively contributed to the catalytic activity of the nanozymes.
Inactivation of the catalyst after 10 min of light irradiation was
consistent with the plateau observed in the substrate conversion
curves of Fig. 3.
As previously reported, FMN alone cannot catalytically
reduce 1 in the absence of light, nor under light irradiation
without electron donor.13 Controls showed that TACN AuNPs
only prompted a 15% substrate conversion in the dark, both
with and without FMN loaded (Fig. S7 and S8, ESI†). Conver-
sely, the nanoscaffold (TACN AuNPs) displayed certain catalytic
activity upon light irradiation, reaching 50–70% conversion in
30 min. Importantly, the reaction efficiency was significantly
lower in terms of TOF value (o0.9 min1) compared to
FMN@TACN AuNPs and free FMN (Fig. S9 and S10, ESI†). High
TOF values under light irradiation are valuable for application
in photochemotherapy since they permit rapid conversion of
Pt(IV) prodrugs with low light doses.
Although further investigation is required, the background
catalytic activity of TACN AuNPs towards the photoreduction of
1 could be reasonably ascribed to an excited-state electron
transfer process promoted by the nanomaterial, considering
that its absorption tail extends over 800 nm (Fig. S2, ESI†).
Undoubtedly, the roadmap to bioorthogonal nanozymes for
the catalytic activation of Pt drugs in complex biological envir-
onments still demands a more refined design than the one
described in this work. Use of these systems in vitro and in vivo
requires that their robustness increases without reducing the
catalytic activity. For instance, inclusion of PEGylated ligands
in the nanoparticle monolayer will likely improve the colloidal
stability and biocompatibility of FMN@TACN and FMN@Zn-
TACN,30 while providing enhanced protection of the FMN
catalyst from the chemical and biological components present
in cells and tissues. While these key aspects are worth exploring
in the future, the results described here highlight that TACN
AuNPs are suitable components to develop supramolecular
nanomaterials capable to carry out unconventional flavin-
mediated catalytic reactions using Pt(IV) prodrugs as substrates.
Besides extending the repertoire of reactions catalyzed by
TACN-based nanoparticles,31–33 this work holds promise as
strategy to control spatio-temporally the effects of Pt anticancer
drugs via light activation and catalytic amplification.
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Fig. 3 Photocatalytic activation of 1 by FMN, FMN@TACN AuNPs and
FMN@Zn-TACN AuNPs. Experimental conditions: [FMN] = 25 mM, [1] = 500 mM,
[MES]pH6 = 5 mM, [TACN]AuNPs = 0 mM or 100 mM, [Zn(NO3)2] = 0 mM or
100 mM, hn 460 nm (5.30 mW cm2). Each point corresponds to an
average of a triplicate of triplicate independent measurements.
Fig. 4 Photobleaching of FMN@TACN AuNPs and free FMN. Experimental
conditions: [FMN] = 25 mM, [1] = 500 mM, [MES]pH6 = 5 mM, [TACN]AuNPs =
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